Lantheus Holdings, Inc. $LNTH Stake Lessened by Isthmus Partners LLC

Isthmus Partners LLC reduced its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 75.3% in the third quarter, Holdings Channel.com reports. The institutional investor owned 10,737 shares of the medical equipment provider’s stock after selling 32,737 shares during the period. Isthmus Partners LLC’s holdings in Lantheus were worth $1,069,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the stock. ABS Investment Management LLC bought a new stake in Lantheus during the 2nd quarter valued at approximately $232,974,000. Western Wealth Management LLC purchased a new position in shares of Lantheus during the 1st quarter worth approximately $25,000. USA Financial Formulas purchased a new position in shares of Lantheus during the 3rd quarter worth approximately $41,000. Allworth Financial LP purchased a new position in shares of Lantheus during the 2nd quarter worth approximately $49,000. Finally, Bessemer Group Inc. grew its holdings in shares of Lantheus by 221.2% during the 1st quarter. Bessemer Group Inc. now owns 514 shares of the medical equipment provider’s stock worth $39,000 after acquiring an additional 354 shares during the period. 99.06% of the stock is owned by institutional investors.

Lantheus Trading Down 0.1%

Shares of NASDAQ LNTH opened at $100.10 on Friday. Lantheus Holdings, Inc. has a 1 year low of $50.15 and a 1 year high of $111.86. The company has a debt-to-equity ratio of 0.43, a current ratio of 3.06 and a quick ratio of 2.89. The firm has a 50-day moving average of $100.32 and a 200 day moving average of $98.58. The stock has a market cap of $6.54 billion, a P/E ratio of 24.18 and a beta of -0.06.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings data on Thursday, August 6th. The medical equipment provider reported $1.55 earnings per share for the quarter, topping analysts’ consensus estimates of $1.30 by $0.25. The business had revenue of $388.18 million for the quarter, compared to analysts’ expectations of $363.23 million. Lantheus had a net margin of 17.69% and a return on equity of 28.10%. The business’s revenue was up 2.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.57 earnings per share. As a group, sell-side analysts expect that Lantheus Holdings, Inc. will post 4.54 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on LNTH. Truist Financial lowered Lantheus from a “buy” rating to a “hold” rating and decreased their target price for the stock from $125.00 to $102.50 in a research report on Monday, August 3rd. William Blair set a $102.50 price target on Lantheus in a research report on Monday, August 3rd. Brookline Capital Markets cut Lantheus from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 28th. B. Riley Financial cut Lantheus from a “buy” rating to a “hold” rating in a research note on Monday, August 17th. Finally, Mizuho reiterated a “neutral” rating and issued a $109.00 price objective (down from $115.00) on shares of Lantheus in a report on Tuesday, October 13th. Three research analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company. Based on data from MarketBeat.com, Lantheus currently has an average rating of “Hold” and a consensus target price of $107.44.

About Lantheus

Lantheus Holdings, Inc is a diagnostic imaging and radiopharmaceutical company that develops, manufactures and commercializes products used to help physicians detect, characterize and monitor disease. Its portfolio supports imaging in areas including oncology, cardiology and other medical specialties.

The company’s products include DEFINITY, an ultrasound-enhancing agent used in cardiac and other ultrasound examinations, and PYLARIFY, a prostate-specific membrane antigen (PSMA) PET imaging agent used to help identify and manage prostate cancer.